<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726241</url>
  </required_header>
  <id_info>
    <org_study_id>APAL2020SC</org_study_id>
    <secondary_id>NCI-2021-00056</secondary_id>
    <secondary_id>APAL2020SC</secondary_id>
    <secondary_id>APAL2020SC</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT04726241</nct_id>
  </id_info>
  <brief_title>A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat</brief_title>
  <official_title>Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to use clinical and biological characteristics of acute leukemias to screen&#xD;
      for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and&#xD;
      blood from patients with leukemia that has come back after treatment or is difficult to treat&#xD;
      may provide information about the patient's leukemia that is important when deciding how to&#xD;
      best treat it, and may help doctors find better ways to diagnose and treat leukemia in&#xD;
      children, adolescents, and young adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To utilize clinical and biological characteristics of acute leukemias to screen for&#xD;
      patient eligibility for available phase I/II Pediatric Acute Leukemia (PedAL) sub-trials.&#xD;
&#xD;
      II. To maintain a longitudinal and comprehensive registry from relapse in children and young&#xD;
      adults with recurrent and refractory leukemia.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment&#xD;
      cycle(s), and at relapse/refractory disease status (if applicable).&#xD;
&#xD;
      After completion of study, patients are followed up every 3 months for 2 years, and then&#xD;
      every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 29, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of a priori specified genomic and immunophenotypic targets to inform sub-trial eligibility</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance of a longitudinal and comprehensive registry from relapse in children and young adults with recurrent and refractory leukemia</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">960</enrollment>
  <condition>Recurrent Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent B Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Mixed Phenotype Acute Leukemia</condition>
  <condition>Recurrent T Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory Mixed Phenotype Acute Leukemia</condition>
  <condition>Therapy-Related Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Observational (biospecimen collection)</arm_group_label>
    <description>Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood and/or bone marrow samples</description>
    <arm_group_label>Observational (biospecimen collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, bone marrow&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known or suspected relapsed/refractory acute myeloid leukemia (AML) or mixed&#xD;
        phenotype acute leukemia, or relapsed acute lymphoblastic leukemia (ALL)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be less than 22 years of age at the time of study enrollment&#xD;
&#xD;
          -  Patient has known or suspected relapsed/refractory AML&#xD;
&#xD;
          -  Patient has known or suspected relapsed ALL that meets the following criteria:&#xD;
&#xD;
               -  Second or greater medullary relapse of B-ALL&#xD;
&#xD;
               -  Any first or greater B or T-ALL medullary relapse involving KMT2A rearrangement&#xD;
                  (KMT2Ar)&#xD;
&#xD;
               -  Any first or greater relapse of T-ALL&#xD;
&#xD;
          -  Known or suspected relapsed/refractory mixed phenotype acute leukemia&#xD;
&#xD;
          -  Known or suspected treatment related AML - de novo or relapsed/refractory&#xD;
&#xD;
          -  All patients and/or their parents or legal guardians must sign a written informed&#xD;
             consent&#xD;
&#xD;
          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute&#xD;
             (NCI) requirements for human studies must be met&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd M Cooper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

